RE:RE:RE:RE:RE:Dr. Coombs and Covid NeilPaert74 wrote: Hempdoc wrote:
enriquesuave wrote: The potential could be enormous, but it's a long shot. If TLD-1433 could kill and neutralize any virus such as Covid or Influenza, then it could act as both a Therapeutic and Vaccine at the same time. IMO. Why, because an infected person would have dead inactivated virus in his body which would serve to stimulate an Immune Response much like a vaccine. No worries about mutations here, as it would not matter. I would suggest an inhaled form of TLD-1433 followed by a chest X-ray which could serve for diagnosing lung lesions and to further activate TLD-1433 killing more virus. ICAM protocol can also be added to reduce any possible cytokine storm. All IMO but Theralase should focus more on NMIBC and if they get Government grants for Viruses then let Dr Coombs advance this at the same time.
Agree...Just to add: I think the long shot potential will not be in the compound's viral killing capacity; its method of killing is scientifically undeniable, & such a killing mechanism allows it to act indiscriminately across viral strains...a huge treatment advantage over current antivirals. The long shot potential imo will be finding an effective/practical therapeutic form of compound delivery, which I also believe should either be in a nebulized or inhaler form...a nebulized form via mask delivery may actually be preferential in the earlier stages of illness. This would allow for more effective compound deposition in the upper airways, including one's nasal passages (where the viral load is highest at this stage). A post treatment sinus x-ray for early stages (in higher risk patients) & a chest X-ray performed in sicker patients (or those with symptoms of lower airway disease) would certainly provide a nice one-two punch : ).
As for investigating vaccine development (based on TLD-1433's mechanism of action), it's certainly an important goal to protect the vulnerable from infection in the first place. However, this type of development could be a much longer & more expensive investment imo. I'd rather get more bang for the buck & have TLT focus primarily on therapeutic development, relying heavily on grant monies. Such a novel breakthrough deserves our attention. The only resources TLT should have to contribute would be financial, & that should be limited based on the grant monies already awarded to Dr. Coombs lab...we just have to let the academic machine take over.
As for an effective/easy-to-use type of vaccine in the future, a nasal form would be desirable in regards to its ability to elicit a mucosal response (the first immune barrier of defense). It is also more kid/needle-averse friendly, especially for big kids like me. Good luck...
I really hope Dr. Coombs shows the world what 1433 can do against viruses this month. Then yeah onward and upward to take on Covid. Along with some grant money maybe $$ ?? Should get them more notoriety and an opportunity to showcase their ACT. Doesn't their ACT for cancer work similarly to how it works against viruses?
Beyond my pay grade...I will let Dr. Coombs & his electron microscope figure that out. But my guess is our compound will act similarly against cancer & pathogens. That special organometallic marriage between Ru + ligand can create healing magic. The special chemistry makes it able to easily intercalate or bind to RNA, DNA, & various proteins/enzymes in a virus or cancerous cell, leading to viral damage/death likely via more than one mechanism & at various stages of the viral life cycle....the cause of damage being more than just ROS-related, whether in the presence of light, or less so in its absence...all the above JMO.
The important takeaway is that 1433 was noted to be highly effective against more than one type (though similar structure) of very harmful virus, even w/o the need for light activation. I'm expecting some really good news (hopefully animal-related) coming out of Dr. Coombs' lab before year end : )